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Abstract
The persistence of symptoms in Lyme disease patients following antibiotic therapy, and their causes, continue to be a
matter of intense controversy. The studies presented here explore antibiotic efficacy using nonhuman primates. Rhesus
macaques were infected with B. burgdorferi and a portion received aggressive antibiotic therapy 4–6 months later. Multiple
methods were utilized for detection of residual organisms, including the feeding of lab-reared ticks on monkeys
(xenodiagnosis), culture, immunofluorescence and PCR. Antibody responses to the B. burgdorferi-specific C6 diagnostic
peptide were measured longitudinally and declined in all treated animals. B. burgdorferi antigen, DNA and RNA were
detected in the tissues of treated animals. Finally, small numbers of intact spirochetes were recovered by xenodiagnosis
from treated monkeys. These results demonstrate that B. burgdorferi can withstand antibiotic treatment, administered post-
dissemination, in a primate host. Though B. burgdorferi is not known to possess resistance mechanisms and is susceptible to
the standard antibiotics (doxycycline, ceftriaxone) in vitro, it appears to become tolerant post-dissemination in the primate
host. This finding raises important questions about the pathogenicity of antibiotic-tolerant persisters and whether or not
they can contribute to symptoms post-treatment.
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Introduction
Lyme borreliosis is caused by the spirochetes of the Borrelia
burgdorferi sensu lato species complex. The clinical progression of
Lyme borreliosis may be divided into early-localized, early-
disseminated, and late stages. During the early-localized phase,
the disease’s most prevalent sign is an erythematous skin rash
known as erythema migrans. Subsequently, patients may develop
early-disseminated disease with dermatologic, rheumatologic,
cardiac, and neurologic involvement. Patients with late disease
present chiefly with arthritis or with neurologic manifestations [1].
The Infectious Diseases Society of America (IDSA) has issued
guidelines for Lyme borreliosis therapy [2]. Signs and symptoms
are usually successfully ameliorated with antimicrobial therapy.
However, some patients continue to have persistent subjective
complaints [3,4] while a few patients fail to respond to antibiotic
therapy, as made evident by signs of persistent infection [2,5]. The
response to treatment in patients with late manifestations is
typically slower [2] and sometimes remains incomplete.
Post-treatment Lyme disease syndrome (PTLDS) is a condition
that occurs in some patients after treatment for Lyme borreliosis.
The cause of PTLDS is currently unknown but prolonged
antibiotic therapy does not seem to be helpful [6,7]. Objective
evaluation of this phenomenon in humans is complicated by the
difficulty in obtaining a patient population with confirmed Lyme
borreliosis treated post-dissemination, and the vague, non-specific
symptoms (fatigue, headache, memory and concentration difficul-
ties, myalgias and arthralgias) with which PTLDS patients present.
In addition, reliable procedures to determine that infection has
been cleared from Lyme disease patients have not been
established.
The C6 ELISA detects antibodies to a region of the B. burgdorferi
VlsE lipoprotein that is immunogenic in infected individuals and
common to all infectious variants tested thus far. Not only is the
C6 test among the most reliable in terms of accuracy, but it is also
a serologic test for Lyme disease that has been used experimentally
as a predictor of treatment outcome [8]. In patients with PTLDS,
anti-C6 titers were found to generally persist at a low level
compared to acute patient titers [9]. To date, the experimental
assessment, in animals, of antibiotic treatment effectiveness,
measured by the presence or absence of spirochetes, correlated
with C6 serologic test reactivity has not been reported.
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late disease or ineffectiveness of repeated treatment in patients
with PTLDS may be formally attributed to several causes,
including: 1) spirochetes that persist in the tissues, likely in small
numbers, inaccessible or impervious to antibiotic; 2) inflammatory
responses to residual antigens from dead organisms; or 3)
autoimmune responses, possibly elicited by antigenic mimicry
[10].
In an effort to gain insight into the viability of these hypotheses,
we designed two experiments in which we respectively assessed the
efficacy of two regimens of ceftriaxone and/or doxycycline
treatment in rhesus macaques commencing at 4–7 months of
infection with B. burgdorferi. Rhesus macaques were chosen because
of the ability of this animal model to reproduce many of the key
signs of human Lyme disease, including neuroborreliosis
[11,12,13,14,15,16,17,18,19,20,21,22] and because of the similar-
ity between the available pharmacokinetics data for ceftriaxone
and doxycycline in rhesus macaques and in humans [23,24,25,26].
Our results confirm that spirochetes are capable of persisting
in treated nonhuman primate hosts. We discuss the possible
mechanisms and need for further inquiry into this phenomenon.
Results
We performed two separate experiments to assess post-
treatment persistence by B. burgdorferi in nonhuman primates with
treatment administered at different phases of disseminated
infection. Both experiments involved infection, treatment post-
dissemination, serology and detection of spirochetes in tissues. The
two varied in the number of animals, B. burgdorferi strain used, time
interval prior to treatment, antibiotic treatment regimen, and
detection methods. The first (Experiment 1) was aimed at
evaluating animals treated at the late disseminated phase of
infection and the treatment regimen was chosen to correspond to
the regimen used to treat human PTLDS patients in a clinical
evaluation of treatment for this population [6]. The outline for
Experiment 1 is depicted in Figure 1.
Experiment 1: Antibiotic treatment in the late,
disseminated phase of infection
Evidence of spirochetal infection. During the first 4 weeks
post-inoculation (PI), skin biopsies were taken weekly to assess
infection by culture. All of the B. burgdorferi-inoculated animals
yielded culture-positive skin biopsies. In addition, antibody in
serum samples that were obtained just prior to the initiation of
antibiotic treatment yielded both a positive B. burgdorferi whole-cell
antigen ELISA, and a positive C6 ELISA in all of the inoculated
animals (not shown).
Evidence that doxycycline had reached the MIC in serum
of treated animals. Serum specimens were obtained from 7
rhesus macaques that were treated with doxycycline as per the
regimen of Experiment 1, and 50 mL of each specimen was tested,
as described in the Materials and Methods section, for relative
concentration. The mean doxycycline concentration at the peak
time (2 h) was 2.07160.431 mg/L or 6.7-fold the MIC of
0.31 mg/L. The median concentration was 2.2 mg/L (range
1.5–2.7). In another experiment, B. subtilis was used as the
indicator strain. Serum specimens were obtained from 5 additional
doxycycline-treated animals both at peak and trough times. The
mean doxycycline concentration at the peak was
0.63060.125 mg/L (median 0.60 mg/L, range 0.45–0.75) and
at the trough (12 h) it was 0.16060.082 mg/L (median 0.15,
range 0.10–0.30). The overall median value of the peak
doxycycline concentration was 1.35 mg/L and ranged from
0.63–2.07 mg/L). Thus, at the peak, the mean concentration of
antibiotic exceeded the MIC in these animals by a factor of 2, but
not at the trough, when it was 0.52-fold the MIC. The serum
concentration of ceftriaxone was not determined. However, the
published concentration of ceftriaxone in rhesus plasma after a
single intravenous dose of 20 mg/Kg varies from over 200 mg/L
Figure 1. Experimental design for assessment of treatment efficacy in the late, disseminated phase of infection (Experiment 1). A)
diagram of animal groups, showing inoculation (B. burgdorferi or sham) and treatment groups (treated with antibiotics or untreated); and B) the time
line of the study.
doi:10.1371/journal.pone.0029914.g001
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and MBC for ceftriaxone with B. burgdorferi sensu stricto (B31) are
0.013 mg/L and 0.050 mg/L, respectively [27]. Therefore, it is
likely that the concentration of ceftriaxone in the rhesus circulation
remained above the MIC and the MBC for a significant portion, if
not all of the 24-h interval between consecutive doses of this
antibiotic.
Distinct patterns in the antibody response to C6. The
antibody response to C6 was measured in serially collected serum
specimens. In all of the infected animals, the C6 antibody index
rose steeply within the first 5–8 weeks post-inoculation (PI)
(Figure 2). Thereafter, the responses fit into three patterns,
depending on whether the animals were or were not treated with
antibiotics. In the treated group, the response declined steadily
during the treatment period and reached background levels at the
endpoint in all animals (Figure 2A, Table 1). In contrast, the
responses of the untreated group remained either largely
unchanged (5 out of 12 animals, Figure 2C, scored positive (+)
Figure 2. Patterns of antibody response to the C6 peptide in infected animals. The C6 index measured as a function of time PI with B.
burgdorferi followed three distinct patterns in Experiment 1. Each graph is the longitudinal antibody response to C6 from one representative animal
for each pattern. In treated (n=12) animals (A) the response declined sharply, almost to background levels, within the antibiotic administration
periods (solid vertical lines, weeks 27–31 for ceftriaxone, weeks 31–39 for doxycycline). In sham-treated animals (B, C) the response either declined,
but independently from the sham treatment intervals, to eventually reach background level (B, n=7), or oscillated throughout the study period
without ever declining steadily (C, n=5). The pattern in (C) corresponds to the C6-positive animals, indicated in Table 1. The dotted lines in B and C
indicate the sham-treatment intervals. The index cut-off value was calculated as described in Material and Methods.
doi:10.1371/journal.pone.0029914.g002
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scored negative (2) in Table 1) but not in parallel with the kinetics
of the treated group’s decline in specific antibody (Figure 2B). The
vertical lines in the figures denote the treatment intervals with
ceftriaxone and doxycycline (Fig. 2A), or sham (Fig. 2B, C). A
comparison of the number of animals with a negative C6 response
postmortem in the treated group (11/11) with those in the
untreated group (7/12) yielded a statistically significant difference
(p=0.0373).
Monitoring of infection status postmortem. Infection
status postmortem was evaluated by culture, PCR, RT-PCR,
gross pathology, histology, and immunofluorescence. All of the
animals were assessed, except one of the animals in the treated
group (AK21), which died due to anesthetic shock 3 months PI.
With regard to culture of spirochetes, one of the treated animals
yielded a positive culture and only one of the untreated animals
was culture-positive (lung tissue).
With regard to PCR, tissues were assessed for spirochetal DNA
by PCR that amplified both the flaB and ospA genes of B. burgdorferi.
Among the untreated group, 2 animals were positive (Table 1).
Here, spirochetal DNA was found in the dorsal root ganglia for
one animal, and in the heart for the other. One of the animals of
the treated group was PCR positive (Table 1), and in several
organs, including the meninges, bladder, spleen, and lungs. The
Table 1. Detection of B. burgdorferi DNA (PCR), antigen by immunofluorescence assay (IFA), anti-C6 serum antibody (C6), B.
burgdorferi RNA (RT-PCR), and inflammatory lesions (by Hematoxylin and Eosin stain (H&E)) in all animals at postmortem, 6 to 12
months after the end of the antibiotic treatment (Experiment 1).
ANTIBIOTIC-TREATED
Animal # PCR RT-PCR IFA
Inflammation
(H&E) C6
AG02 22 2 2 2
AG48 2 + (h, b) 22 2
AH77 22 + (h) 22
AI97 + (m, bl, s, l) + (h) + (m, h) 22
AK21 NA NA NA 22
AL06 22 + (h) + (h) 2
AL70 22 2 2 2
AL82 22 + (m, h) + (h) 2
AM38 22 + (m, h) + (h) 2
BF20 22 + (m, h) 22
BF21 22 2 2 2
BH50 2 + (h) + (h) 22
BR97 (uninf.) 22 2 2 2
BR99 (uninf.) 22 2 2 2
SHAM-TREATED
Animal # PCR RT-PCR IFA
Inflammation
(H&E) C6
BD71 22 + (h) 2 +
BG03 22 + (h) 2 +
BG48 22 + (m, h) 2 +
BG96 22 + (m, h) 22
BH18 22 + (m, h) 22
BH19 22 2 2 2
BH31 2 + (h) + (m, h) 2 +
BH79 22 2 2 2
BI80 22 + (m, h) 22
BT02 + (drg) 22 2 2
V517 2 + (b) + (m, h) 22
BE40 + (h) 2 + (m, h) 2 +
AH79(uninf.) 22 2 2 2
V789(uninf.) 22 2 2 2
b, brain; bl, bladder; drg, dorsal root ganglia; h, heart; l, lung;
m, meninges; s, spleen.
(uninf.): animals not inoculated with B. burgdorferi.
NA: sample not available.
doi:10.1371/journal.pone.0029914.t001
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statistically significant (p=1.000).
For detection of B. burgdorferi transcript, RNA was extracted
from heart and brain specimens. Two of the animals that were not
treated with antibiotics were positive, one in heart and the other in
brain. Two of the treated animals had detectable spirochetal RNA
in the heart, and one additional treated animal was positive for B.
burgdorferi RNA in both heart and brain (Table 1). The difference
was not statistically significant (p=0.6464).
In the assessment of gross pathology, histology, and immuno-
fluorescence, no gross lesions were observed in any of the animals.
Fragments of heart and meninges were collected postmortem, and
fixed, sectioned and stained for histology and immunofluores-
cence. Three animals, all of them treated, had moderate to severe
inflammatory lesions in the heart (Table 1, Figure 3A). Positive
immunofluorescent staining for B. burgdorferi appeared as frag-
ments. Serial sections of tissue were cut at 6 mm width, so only
bacteria lying perfectly parallel to the section would appear as 12–
17 mm in length (the reported length of B31 spirochetes [28]
(Figure 3B). We did not find samples of this type. However, there
were numerous immunofluorescence-positive specimens both in
the untreated and the treated groups (Table 1). The difference was
not statistically significant (p=0.6668). The four animals that were
not inoculated with B. burgdorferi were negative by this test (Table 1).
Experiment 2: Antibiotic treatment in the early,
disseminated phase of infection
The second experiment (Experiment 2) focused on animals
treated at the early disseminated phase and the duration of the
treatment regimen was chosen by the IDSA guidelines [29]. The
dose of doxycycline given was markedly higher than in
Experiment 1. In addition to molecular methods, xenodiagnosis
was used for detection of infection. The experimental outline is
depicted in Figure 4.
Confirmation of B. burgdorferi infection. In Experiment
2, skin biopsies and blood were taken at 1–4 weeks PI. Skin
samples were cultured in BSK-H medium and subjected to DNA
extraction for Borrelia-specific PCR. Seroconversion was tested by
ELISA for antibody reactivity to the C6 peptide [30], the Ct
peptide (a 51-mer synthetic peptide that reproduces the entire
sequence of the C-terminal invariable domain of VlsE from B.
burgdorferi strain B31) [31] and outer surface protein C (OspC) [32].
Infection was indicated by Borrelia DNA detection in skin biopsies
and by serology (Table S1). Cultures were kept 12–15 weeks, but
none were positive for spirochete growth.
Decrease in anti-C6 antibody titers with treatment. We
measured the responses to C6 longitudinally to include before,
during, and after treatment. The endpoint dilution titers were also
determined for the final time point (week 47 for Experiment 2).
The C6-specific antibody levels declined in all animals treated with
antibiotics (Figure S1). In untreated animals, the anti-C6 responses
either leveled off or slowly declined. To determine if antibody
titers declined to baseline, the endpoint dilution titers for each of
the five animals in Experiment 2 were determined for sera
collected before, during, and after treatment. For all of the
untreated animals, the titers remained high and the titers from the
treated animals declined markedly, and remained at low level even
at 27 weeks post-treatment (Table 2).
Detection of spirochetes in treated animals by
xenodiagnosis. At 7 and 11 months PI, all monkeys were fed
upon by Ixodes scapularis nymphs for the uptake of persisting
spirochetes by xenodiagnosis. The number of nymphs that fed to
repletion varied considerably between animals. For the first round,
a total of 7, 8, and 11 ticks, respectively, fed on the treated
animals, whereas only 5 ticks fed on each of the untreated animals
(Table S2). Tick midguts were split into 3 parts for culture, direct
fluorescence and for DNA extraction. The probability of
recovering spirochetes would be higher from animals upon
which more ticks feed. As such, intact spirochetes were detected
from the cultured midgut contents (Figure 5A) or directly from tick
midgut smears (Figure 5B) of two animals at 7 months PI, both of
which had been treated. These animals (GB56 and GA59) also
had the most xenodiagnostic ticks feed (Table S2).
Detection of spirochetal nucleic acids in tissues. For
Experiment 2, several B. burgdorferi genes were used both for
detection of spirochetes (by standard PCR) and for detection of
metabolically active spirochetes (by RT-PCR). The detection of
genes throughout the course of infection, in tissues, by standard
PCR/RT-PCR is shown in Figure 6.
The ospC gene was amplified from skin biopsy tissue from each
animal in at least one of the four samplings (Figure 6A) shortly
after inoculation. These results confirmed infection and specific
Figure 3. Images of tissue inflammation and B. burgdorferi antigen in tissues from animals treated in the late, disseminated phase
(Experiment 1). For antigen detection, samples of tissue were stained for fluorescent detection (IFA) with anti-B. burgdorferi monoclonal (see
Materials and Methods) antibody. (A) Hematoxylin &Eosin stain showing monocytic and lymphocytic infiltrate in a heart section (206) of a treated
animal (AM38). (B) Image of positive IFA staining from the heart tissue of the same animal.
doi:10.1371/journal.pone.0029914.g003
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nucleic acids by PCR was also performed on xenodiagnostic tick
midgut samples (Figure 6B). For treated animal FK38, spirochetal
DNA was detected by amplification of ospC from midgut contents
when organisms were not detected by culture or DFA (Figure 6B).
A few spirochetes grew in cultures of organ tissues collected
post-mortem from each animal after .9 weeks, but we were
unable to subculture any spirochetes from either treated or
untreated animals due to their slow growth. We therefore pelleted
these cultures to confirm their identity and test their viability by
DNA/RNA analysis. Transcription was detected in culture pellets
and the tissues of treated animals, indicating that the bacteria were
metabolically active (Figure 6C, D). Figure 6D shows ospA
transcription detected directly in tissues harvested from treated
and untreated animals. We also hypothesized that persistent
spirochetes may lose linear plasmid 28-1 (lp28-1), which encodes
the VlsE antigen bound by the anti-C6 antibody. Transcription of
a lp28-1 gene (bbf26) was verified in organ tissue from both
untreated animals and one treated animal (Figure 6D).
Discussion
In some cases, patients who have been treated for Lyme disease
experience persistent symptoms. The assertion that further
antibiotic treatment is warranted in these cases is a matter of
contention and considerable debate [33,34,35,36]. Our results
indicate that disseminated spirochetes of two different B. burgdorferi
strains can persist in the primate host following high dose, or long-
lasting antibiotic therapy. In terms of disease, only objective signs
of disease post-therapy may be measurable in an animal model.
While we did not find gross signs of disease postmortem, in
Experiment 1 we did identify heart sections with inflammatory
infiltrates in three of the treated animals. In addition, several
animals, both treated and untreated showed sections of heart and
meninges that were positive by immunofluorescence for B.
burgdorferi. At the molecular level, B. burgdorferi DNA would
indicate the presence of organisms, live or dead. The detection
of RNA, however, should indicate that those present are
metabolically active and thus alive. In Experiment 1, spirochetal
DNA and RNA were detected in the tissues of a few animals,
independent of treatment. This may reflect a low spirochetal
burden, lack of flaB transcription [37], and/or seclusion in
untested tissues.
In Experiment 2, we were able to recover spirochetes by
xenodiagnosis in two of the three treated animals. The inability to
recover spirochetes from all five macaques could be in part
attributed to the number of ticks that fed, which was markedly
smaller for untreated animals (Supplementary Table S2). Howev-
er, a few slow-growing organisms were recovered by culture from
each animal. We detected the ospA transcript in culture pellets
from tissues of four animals and directly from at least one tissue
from each animal. We chose ospA because this gene has been
shown to be transcribed by host-adapted B. burgdorferi [38], in
disseminated infection [39], and because of the induction of an
anti-OspA response in patients [40] post-dissemination.
The nature of the persistent organisms and the acquisition of
tolerance to antibiotics are questions that need to be addressed.
The B. burgdorferi spirochete is known to invade collagenous tissue
as a possible mechanism of immune evasion. It has been
postulated that the joint tissues provide a protective niche during
antibiotic treatment [41]. Our studies and others [37,42],
however, have not demonstrated a specific predilection for
spirochete presence in joints of treated animals. Antibiotic
tolerance has been demonstrated in vitro with several bacterial
species, both gram negative (E. coli) and gram positive (Staphylo-
coccus spp.). The fact that organisms can persist in the presence of
antibiotics such as penicillin and cephalosporins (ceftriaxone) that
interfere with cell wall synthesis appears to stem from their ability
to enter a dormant, non-dividing state [43,44], thus avoiding the
Figure 4. Experimental outline and sample collection for
assessment of treatment efficacy in the disseminated phase
of infection (Experiment 2).
doi:10.1371/journal.pone.0029914.g004
Table 2. Reciprocal end-point dilution titers of anti-C6
antibodies in antibiotic-treated* (bold) and untreated
macaques infected with B. burgdorferi (Experiment 2).
16 weeks PI 32 weeks PI 47 weeks PI
GA59 .2560 640 320
FK38 .2560 40 160
GB56 .2560 160 320
GC84 .2560 .2560 .2560
FT47 .2560 .2560 .2560
*treatment was given during weeks 16–20.
doi:10.1371/journal.pone.0029914.t002
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antibiotic that was used in these experiments is doxycycline. The
tetracycline class of antibiotics corrupts translation at the
ribosome; therefore, minimal gene expression from dormant
organisms may be unaffected. A ‘‘persister’’ phenotype may
possibly be responsible for the recalcitrance of persisting
spirochetes made evident by previous studies in mice and dogs
[37,42,45], and by those presented in this report. Perhaps
incomplete clearance of bacteria following antibiotic treatment is
not a phenomenon unique to B. burgdorferi, but one that occurs
Figure 5. Spirochetes recovered by xenodiagnosis from animals treated in the disseminated phase of infection. Images from direct
fluorescent staining of B. burgdorferi spirochetes found in xenodiagnostic tick midgut culture (A) or tick midgut preparation (B) from treated animals
GA59 and GB56, respectively.
doi:10.1371/journal.pone.0029914.g005
Figure 6. Nucleic acid detection of B. burgdorferi (Experiment 2). Detection by PCR or RT-PCR using primers for the indicated genes from: A)
skin biopsy samples; B) xenodiagnostic ticks; C) organ tissue culture pellets; and D) directly from tissues known to harbor the spirochetes. Animal
numbers in bold are of those that were treated. Asterisks indicate clear positive amplimers.sk=skin; h t=heart; bl=bladder; spl=pleen. Labels
include: M=marker (100 bp ladder); (+)=B.burgdorferi, strain B31 DNA/RNA; ssc=spirochete strain negative control (Bb strain JD1 DNA); ntc=no
template control; tnc=tick negative control; uim=uninfected monkey DNA/RNA.
doi:10.1371/journal.pone.0029914.g006
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enables detection of otherwise inconspicuous live organisms
through acquisition by the natural vector.
To date, the C6 ELISA is the only test in which a decline in
antibody titer is statistically associated with outcome of antibiotic
treatment [8,46,47]. In accord with this finding, we observed a
distinct and rapid decline in C6 titer in all antibiotic-treated
animals. Not all animals, however, were spirochete-free, so the
question of what facet of infection is indicated by anti-C6 antibody
titers was brought to the fore. Also, the C6 titers declined in some
untreated animals over a long period of time, but not in others,
though presence of spirochetes was indicated in C6-negative
untreated animals by IFA or PCR/RT-PCR. This is likely due in
part to genetic differences in outbred animals. Possible explana-
tions for the lack of correlation between C6 response and presence
of spirochetes include: (1) the anti-C6 titer is an indicator of
treatment efficacy and the infection is cleared despite the presence
of spirochetal genetic material/antigen; (2) organisms persist and
the anti-C6 titer does not reflect their presence, perhaps due to loss
of plasmid lp28-1 (which encodes VlsE, the parent molecule of
C6); or (3) anti-C6 titer declines with a significant reduction in
spirochetal burden, but a low number of organisms reside in the
host; if these organisms are dormant, then transcription of vlsE also
may be negligible, minimizing re-stimulation with antigen. The
detection of intact organisms ruled out the first explanation and
detection of transcript (bbf26) from lp28-1 disproves that
explanation #2 may be operating exclusively. We therefore favor
explanation #3 and seek to determine the level of transcriptional/
metabolic activity, and pathogenicity of persistent organisms. If,
for example, spirochetes that are recovered by xenodiagnosis from
treated animals turned out to be non-pathogenic, this would
validate the decline in C6 titer as a measure of successful treatment
outcome.
In infected mice treated with tigecycline, transcription of the
chromosomally-encoded B. burgdorferi oppA2 gene was detected in 8
of 9 treated mice, indicating spirochetal viability [37]. Importantly,
these studies also indicated that DNA copies of another gene, ospA,
were present in treated mice, but were significantly fewer than in
untreated mice. This result likely reflects a much lower spirochetal
burden with treatment, supporting the notion that anti-C6 titer
may decline as a function of reduced numbers. The C6 titers in
these mice were not determined. Due to the relatively small
quantities of bacteria over a large amount of tissue, we were
unable to reliably quantify DNA or transcript levels in nonhuman
primates. Similarly, the recovery of few spirochetes by tissue
culture is aptly a reflection of the rhesus model and not necessarily
the treatment [48].
The most pressing question in terms of human disease is
whether or not spirochetes remain pathogenic after antimicrobial
therapy. Similarly, do spirochetes persist long-term, or are they
eventually cleared by the host? Clearly, the phenotype of persistent
organisms needs to be elucidated. These studies support the use of
the C6 test for diagnosis and measurement post-treatment;
however, the absolute quantification of antibody levels may be
essential in determining treatment efficacy for PTLDS patients, as
low levels (yet above baseline) may indicate presence of residual
spirochetes or antigen. Finally, the use of variable and pulse-dosing
regimens of antibiotics may improve efficacy [43] and this
warrants testing in an appropriate model.
Finally, in these studies we used an artificial mode of inoculation
and spirochetal dose. The experimental results must be confirmed
with tick-mediated infection, which is our intent. Our studies do
however offer proof of the principle that intact spirochetes can
persist in an incidental host comparable to humans, following
antibiotic therapy. Additionally, our experiments uncover residual
antigen associated with inflammatory foci. Whether persistent
spirochetes or spirochetal antigen can cause PTLDS remains
unanswered.
Materials and Methods
Ethics statement
Practices in the housing and care of animals conformed to the
regulations and standards of the PHS Policy on Humane Care and
Use of Laboratory Animals, and the Guide for the Care and Use
of Laboratory Animals. The Tulane National Primate Research
Center (Animal Welfare Assurance # A4499-01) is fully accredited
by the Association for the Assessment and Accreditation of
Laboratory Animal Care-International. The Institutional Animal
Care and Use Committee (IACUC) of the Tulane National
Primate Research Center approved all animal-related protocols,
including the infection, treatment, and tick-feeding procedures
used with nonhuman primates. All animal procedures were
overseen by veterinarians and their staff. For blood collection,
skin biopsy collection and the tick capsule procedures, monkeys
were anesthetized with ketamine (10 mg/kg) by intramuscular
injection. Animals were humanely euthanized by the veterinary
staff at the TNPRC in accordance with endpoint policies.
Euthanasia was conducted by anesthesia with ketamine hydro-
chloride (10 mg/kg) followed by an overdose with sodium
pentobarbital. This method is consistent with the recommendation
of the American Veterinary Medical Association guidelines.
Experimental design
In the first experiment (Experiment 1), the treatment regimen
was initiated at 27 weeks PI. It included the administration of
ceftriaxone for 30 days, followed by 60 days of doxycycline. The
latter antibiotic is used primarily to treat early localized and
disseminated disease, whereas ceftriaxone is used to treat late
disease [2]. Animals were kept for a minimum of 6 months after
treatment termination. Tissue samples were collected for 1) in vitro
culture of B. burgdorferi; 2) quantitative real-time PCR and reverse
transcriptase (RT)-PCR, for detection of B. burgdorferi nucleic acids;
and 3) histopathology/immunofluorescence to localize inflamma-
tory lesions and spirochetes in tissues, respectively. The C6 test
was also performed on serum specimens collected serially from all
of the animals.
In the second experiment (Experiment 2), the treatment
regimen began 4 months after inoculation with B. burgdorferi and
consisted of a 28-day regimen of oral doxycycline, as per the IDSA
guidelines for disseminated infection [2]. At 7 and 11 months PI,
xenodiagnosis with I. scapularis ticks was performed. Serum was
collected throughout the study period and tested for reactivity
against the C6 peptide. Following euthanasia, tissues were cultured
and tested by PCR and RT-PCR for detection of spirochetes and
spirochetal nucleic acids.
Animals, spirochetal inoculation, animal groups, and
antibiotic treatment
Experiment 1. Twenty-eight rhesus macaques (Macaca
mulatta) of Chinese origin were used in this study. Their median
age when assigned to the study was 2.22 years (range 1.25–4.32).
Three of the animals were females and the rest males. All were
singly caged, fed commercial monkey chow (Purina Mills 5037 R),
and had water available ad libitum.
For inoculation, B. burgdorferi spirochetes of the JD1 strain [49]
were grown in BSK-H medium (Sigma-Aldrich, St. Louis, MO) up
to stationary phase (,10
8 cells per mL). Twenty-four animals were
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8 spirochetes each via needle and
syringe, with 10
8 organisms given intraperitoneally in the lower
right quadrant, 10
8 subcutaneously in the same injection site, and
2610
7 intradermally, also in the same site. An additional 10
8
spirochetes were given subcutaneously in the dorsal cervical
midline. Four animals were sham-inoculated as uninfected
controls. The inoculation and treatment design is summarized in
Figure 1A. At 27 weeks PI, 12 of the infected animals and two of
the controls were treated with ceftriaxone, followed by doxycy-
cline. Animals received intravenous ceftriaxone, 25 mg/kg, once
per day for 30 days (Ceftiofur sodium, Pfizer Animal Health,
Kalamazoo, MI) followed by 60 days of oral doxycycline, 2 mg/
kg, twice per day (Bio-Serv, Frenchtown, NJ). Twelve infected and
2 control animals were sham-treated. Animal euthanasia began
approximately six months post-termination of treatment. Within
an additional six-month period all of the animals had been
euthanized. The complete time line of the study is depicted in
Figure 1B.
Experiment 2. Five male rhesus macaques (Chinese origin),
3–4 years of age, were used for the second experiment (outlined in
Figure 4C). Four animals were pair-housed after observation
under protected contact, and one (GB56) was housed alone. Each
animal was given 3 inoculations in the ventral midline of in vitro-
cultured late log-phase B. burgdorferi strain B31, isolate 5A19 [50]:
two subcutaneous 1.0 mL injections and one intradermal 0.1 mL
injection, each containing 1610
8 organisms diluted in sterile
Hanks Balanced Salt Solution (HBSS), for a total inoculum of
3610
8.
At four months PI, three of the five animals received antibiotic
treatment. Animals were trained to accept treats in which the
tablets were concealed. Each of the three treated macaques was
given one 50 mg tablet of doxycycline (Bio-Serv) twice/day for 28
consecutive days. This dose corresponded to .12 mg/kg/day to
ensure that an effective blood level was achieved.
Determination of the serum concentration of doxycyline
in vivo
In vitro-cultured B. burgdorferi do not grow well in the presence
of monkey serum, so antibiotic concentrations in serum had to be
tested with alternative reporter strains of bacteria. A 0.5 McFar-
land suspension of bacteria (Staphylococcus aureus, ATCC #29213 or
Bacillus subtilis, ATCC #6633), made in Mueller-Hinton broth
(BD, Franklin Lakes, NJ), was streaked onto Mueller-Hinton agar
plates (BD). The streaking was done so that a confluent ‘‘lawn’’ of
bacteria would grow after 18–24 hours of incubation at 37uC. To
determine antibiotic concentration in serum, 50 mL of serum from
treated animals was applied to 6-mm diameter plain paper discs
(BD) and allowed to dry for 30 minutes. Standards were made by
dissolving doxycycline hyclate (Sigma-Aldrich) into normal
monkey serum; these were applied to the discs in the same
manner. Standard doxycycline concentrations were 2, 5 and 10-
fold the B. burgdorferi minimum inhibitory concentration (MIC)
when S. aureus was used, and 0.5, 1, and 2-fold the MIC when B.
subtilis was used. Both indicator strains were used in order to
expand the range of detection. The doxycycline MIC for the JD1
strain of B. burgdorferi was determined to be 0.310 mg/L, which
was approximately the same as the mean value of 0.327 mg/L
that had previously been obtained for several strains and species of
B. burgdorferi sensu lato [27].
The test discs were placed onto the prepared agar plates and
incubated overnight at 37uC. The zones of inhibition were
measured in radial mm. A standard curve was generated using the
measurements of the control/standards. The test measurements
were compared to the standard curve giving an approximate
doxycycline concentration from the test serum. Serum from
treated animals was obtained both at the times of peak and trough
concentrations for doxycycline, namely, at 2 h and 12 h post-dose
administration, during the 8
th week of doxycycline treatment. Peak
and trough times for rhesus macaques were as per Kelly et al. [51],
who in turn based their estimations on pharmacokinetic data from
humans.
Culture of skin biopsy and organ specimens
In both experiments, 4 mm skin biopsy specimens were
collected from all animals, under anesthesia, weekly during the
first four weeks PI and were cultured in BSK-H medium as
described [11]. Skin biopsy samples were thus collected from live
animals before antibiotic treatment so as to confirm infection.
Organ specimens were also collected at necropsy. In Experiment
1, the following organ specimens, obtained postmortem, were
cultured: brain (20 samples per monkey), meninges (10), dorsal
root ganglia (5), sciatic nerve (10), skin (10), heart (10), synovial
membrane (2), peritoneal membrane (10), lung (5), bladder (5), and
spleen (5). In Experiment 2, specimens of skin, heart, bladder,
spleen, knee joint synovial membrane, and shoulder tendon were
cultured. Two ,2m m
3 tissue sections from each organ were
cultured.
Detection of spirochetal DNA
In Experiment 1, real time PCR targeted at the ospA and flaB
genes was performed following a protocol described previously
[52]. DNA extracted from up to ten specimens each of brain,
meninges, dorsal root ganglia, sciatic nerve, skin, heart, synovial
membrane, peritoneal membrane, lung, bladder, and spleen was
amplified for all animals postmortem. Only those specimens that
were positive for both the ospA and flaB genes were considered
positive.
In Experiment 2, standard PCR was used for detection of B.
burgdorferi from tick midguts, culture pellets and animal tissues.
DNA was extracted from ,60 mg (30 mg62) of each tissue (heart,
bladder, spleen, knee joint synovium, shoulder tendon and skin)
with the DNeasyH Blood and Tissue kit (Qiagen, Valencia, CA).
Primer sets that target the flaB and ospC genes were used and are
published [53]. The Taq DNA polymerase Core Kit (Qiagen) was
utilized according to the manufacturer’s protocol. For each
primer, 0.4 mM concentration was used. PCR was performed
with 35 cycles of denaturation (94u, 30 sec.), annealing (43–53u,
45 sec.) and extension (72u, 1 min.). Negative controls included
DNA extracted from uninfected monkey tissue (from Experiment
1) and DNA extracted from a pool of 5 ticks derived from the same
egg mass as those used for xenodiagnosis.
Detection of spirochetal transcripts by reverse
transcriptase PCR
For Experiment 1, total RNA from heart and brain specimens
from all of the animals at postmortem was isolated using the Trizol
method (Invitrogen, Carlsbad, CA) and contaminating DNA was
removed from 2–5 mg of total RNA specimens using the DNA-
free
TM kit, according to the manufacturer’s protocol (Applied
Biosystems/Ambion, Austin, TX). cDNA was subsequently
synthesized from 1 mg of DNA-free RNA using the iScript cdNA
synthesis kit (Bio-Rad, Hercules, CA). No amplicon was obtained
by the procedure described below when the cDNA synthesis step
was omitted. One ml of cDNA from each of the monkey tissue
samples served as template to PCR amplify a 275 bp fragment of
the B. burgdorferi flagellin (flaB) transcript. The forward primer was
59-TTGCTGATCAAGCTCAATATAACCA-39 and the reverse
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performed using Taq polymerase (Roche, CA). The cycling
conditions were as follows: 1 cycle of denaturation at 94uC for
3 min followed by 35 cycles of 30 sec denaturation at 94uC, 30 sec
annealing at 60uC and 30 sec extension at 72uC and one cycle of
5 min extension at 72uC. PCR products were electrophoresed on
a 1.5% agarose gel and the gel processed for Southern blotting as
described [54]. Separated amplicons were capillary transferred to
Hybond N+ nitrocellulose membrane (Amersham Biosciences,
Buckinghamshire, UK) as described [54]. A 22-mer oligonucleo-
tide corresponding to a sequence within this amplicon (59-
CTGCTTCTCAAAATGTAAGAACAGCTGAAGAGCTTG-
39) was synthesized at the W. M. Keck Facility at Yale University
and non-radioactively labeled using the Gene Images AlkPhos
Direct Labeling and Detection system (Amersham Biosciences,
UK). The labeled probe was hybridized to the nitrocellulose
membrane at 55uC overnight and washed as described in the
manual (Amersham Biosciences, UK). Hybridization and washings
were performed in hybridization bottles in a hybridization oven
(Labnet International, Woodbridge, NJ). Bound probe was
detected using the CDP-Star detection reagent for chemilumines-
cent detection of alkaline phosphatase (Amersham Biosciences,
UK). Two independent RNA preparations were obtained from
heart and brain tissues. Tissue specimens were considered positive
only when they were positive in both preparations.
In Experiment 2, standard RT-PCR detection was used. RNA
was extracted from the tissues with the RNeasyH Fibrous Tissue
Mini Kit and treated with the RNase-free DNase set (Qiagen) to
remove any residual DNA. The ospA and bbf26 genes were
amplified, using the following primers: (1) ospA forward primer 59-
AATGTTAGCAGCCTTGACGA-39; reverse primer 59-TC-
GTACTTGCCGTCTTTGTT -39; (2) bbf26 forward primer 59-
TGCCTCTAATTGTGAACACC-39; reverse primer 59-TC-
AAATCTTGAACAATACACTCA-39. RT-PCR was performed
with the QiagenH OneStep RT-PCR kit. A quantity of 100–
250 ng total RNA was used as template, with primer concentra-
tions of 0.8 mM (forward) and 1.2 mM (reverse). The cycling was
carried out per manufacturer’s suggestion with the GeneAmp
PCRSystem 9700 (Applied Biosystems, Carlsbad, CA). Each set
produces a ,100 bp amplicon. Samples of RNA from monkey
tissue and B. burgdorferi cultures were tested for DNA contamina-
tion by PCR amplification using Taq polymerase and none was
detected (Figure S2).
Detection of anti-C6 antibody
Anti-C6 serum antibody levels were quantified in all animals
starting prior to inoculation and then serially thereafter until post-
euthanasia. The ELISA procedure used has been described [55].
In Experiment 1, monkey serum was used at a dilution of 1:800 for
all time points. The cut-off ELISA value for each plate was set as
the mean of the optical density at 450 nm (OD450) of duplicate
determinations of pre-immune serum specimens from 7 animals
plus 36the standard deviation (SD). To correct for plate-to plate
variations, a reference positive control serum pool was also
included in each plate, in triplicate. This pool was made by
combining equal volumes of serum that was obtained from 24
animals inoculated with B. burgdorferi. The aliquots for the pool
were from serum specimens that were obtained from each animal
on two consecutive collection dates just prior to the initiation of
antibiotic treatment. The mean OD450 of the triplicate determi-
nation for each plate was used as a divisor for all of the OD450
values obtained with that plate, including the cut-off value, and
values were reported as a quotient (index).
In Experiment 2, the same peptide antigen (C6), here derived
from the strain B31 sequence, and ELISA procedure as in
Experiment 1 was used. However, all responses could be
compared on one plate, so the conversion to an index value was
not required. Blood was collected at the following time points: 0, 2,
6, 10, 14, 16, 18, 22, 26, 28, 34, 40 and 47 weeks PI. Monkey
serum was used at a 1:400 dilution for standard ELISA and at 2-
fold dilution (in 5% pre-immune serum) from 1:40 through 1:2560
for endpoint dilution titers. The mean OD450 value of triplicate
pre-immune serum samples from each individual animal was
subtracted from the value at each time point or dilution for that
animal. The reported end-point dilution titer is the dilution at
which the sample reached the highest OD450 value for pre-
immune serum+26 the SD obtained from that animal. In
addition, serum from 2 weeks PI was tested for antibody to the
Ct peptide [56] and OspC by ELISA, as described [56,57].
Recombinant OspC was kindly provided by Robert Gilmore
(CDC, Fort Collins, CO).
Detection of antibody to B. burgdorferi whole-cell
antigen extract (Experiment 1)
B. burgdorferi antigen was extracted from spirochete cells by
sonication in PBS, and dispensed onto 96-well ELISA plates
(CorningH CostarH, Lowell, MA) at 100 mL/well (0.1 mg protein)
in 50 mM carbonate buffer pH 9.6 overnight at 4uC. Plates were
washed with 0.1% Tween 20 in PBS (PBS/T) and blocked for 1 h
with 200 mL of 5% nonfat dried milk in PBS/T in a rotating plate
set at 100–150 rpm. Serum specimens from bleeds obtained prior
to inoculation, immediately prior to antibiotic treatment initiation,
and at necropsy were diluted in PBS/T and tested at dilutions of
1:800 and 1:3200. Antibody bound to the plate was reacted with
horseradish peroxidase-labeled goat anti-monkey IgG (gamma
chain-specific, Kirkegaard and Perry Labs, (KPL), Gaithersburg,
MD) at a dilution of 1:5000, for 1 h, followed by TMB Microwell
Peroxidase Substrate System (KPL). The color reaction was
allowed to proceed for 8–9 min, and stopped by adding 100 mL
per well of 1.0 M phosphoric acid. OD450 was measured on a
plate reader (Biotek Instruments, Winooski, VT).
Gross pathology assessment (Experiment 1)
Several organs were assessed for gross pathology by a veterinary
pathologist, including heart, lungs, spleen, liver, musculoskeletal
system, bladder, kidneys, peripheral lymph nodes, brain and
meninges.
Detection of inflammatory lesions and spirochetal
antigen in tissues (Experiment 1)
To detect inflammatory lesions in heart and meninges that were
collected postmortem, tissue fragments were fixed in Z-fix
(Anatech Ltd., Battle Creek, MI), embedded in paraffin, sectioned
at 6 mm, and stained with hematoxylin and eosin. Stained sections
were evaluated under a light microscope using 4–406magnifica-
tion and a Leica microscope with a SPOT Insight digital camera
(Digital Instruments Inc., Michigan, USA). To detect spirochetal
antigen a monoclonal antibody (MAb 240.1) was used. This IgG1
MAb reacts with a 7.5 kDa B. burgdorferi lipoprotein [58] and had
been employed before by us to detect B. burgdorferi antigen by
immunohistochemistry [13]. Deparaffinized sections were washed
with PBS containing 0.2% fish-skin gelatin and 0.1% Triton X-
100 (PBS-FSG-Tx100) at room temperature for 10 minutes.
Sections were then blocked with 10% normal goat serum (NGS)
diluted in phosphate buffered saline containing 0.2% fish skin
gelatin (PBS-FSG) in a humidified chamber, also at room
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NGS and incubated for 1 hour at room temperature in a
humidified chamber protected from light. Following incubation
the slides were washed twice with PBS-FSG-Tx100 for ten minutes
each. B. burgdorferi immunofluorescence was revealed using a
species-specific goat anti-mouse secondary antibody coupled with
Alexa 488 (Molecular Probes, Eugene, OR). The secondary
antibody was also diluted in 10% NGS and incubated in a
humidified chamber for 40 minutes at room temperature
protected from light. Following incubation, the slides were washed
twice with PBS-FSG-Tx100 for ten minutes each and followed
with PBS-FSG. Upon completion of immunofluorescence staining,
the sections were rinsed in doubly distilled water and mounted in
an anti-quenching solution composed of 0.33 g/mL glycerol,
analar grade, 0.133 g/mL MOWIOL 4–88 (Calbiochem), 33.33%
double distilled water, 66.66% 0.2 M Tris Buffer, and 25 mg/mL
DABCO (1.4-diazobicyclo-[2.2.2.]-octane) (Sigma-Aldrich) and
coverslipped.
Xenodiagnosis
In Experiment 2, xenodiagnosis was performed at 7 and 11
months PI, which translated to 2 and 6 months after cessation of
treatment. At 27 weeks PI, nylon-mesh jackets that zip in the back
(Lomir Biomedical, NY) were placed on each of the five animals
for acclimatization. At 28 weeks PI, 10 laboratory-reared nymphal
Ixodes scapularis ticks were placed on the back of each animal
through a containment capsule by a procedure that has been
described [11]. Briefly, the area of the back to be used for tick
placement was shaved and wiped with SkinPrep (Smith & Nephew
Medical, UK). The tick containment capsule was fixed to the skin
at its base with Super Glue and at the edges with SkinBond
contact adhesive (Smith & Nephew Medical). The capsule was
further secured into place with Hypafix tape (Smith & Nephew
Medical). The ticks were placed inside the capsule on the skin and
sealed over with a piece of nylon mesh and screw cap lid, so that
ticks could not escape from the capsule. The average feeding time
for ticks is 72 hours, so to allow time for them to feed to repletion,
they were removed 4 days later. For tick removal, the capsules
were opened and ticks were collected with a paintbrush. Ticks that
had not detached from the skin were removed carefully with
forceps. The capsules were gently removed by dissolving the
adhesive with UniSolve (Smith & Nephew Medical) so as not to
irritate the skin.
Ticks were washed with 1% sodium hypochlorite, 0.5%
benzalkonium chloride and 70% ethanol for 1 min each and
crushed in 45 mL PBS with a microfuge pestle. The contents were
split into three 15-mL portions for: (1) direct fluorescence assay
(DFA); (2) culture; and (3) PCR. For DFA, the samples were
smeared on microscope slides, dried and fixed with acetone. The
samples were stained with an anti-Borrelia-FITC antibody (KPL)
and examined by fluorescence microscopy to detect the presence
of spirochetes [59]. For culture, samples were added to ,4m L
BSK-H medium and incubated for 8 weeks at 34uC, in the
presence of 5% CO2 and influx of N2 to produce a microaero-
philic environment.
Statistical analysis (Experiment 1)
Differences between treated and untreated animals in detection
results of spirochetal DNA, RNA, antigen, and in the C6 antibody
response at postmortem were evaluated with Fisher’s exact test
(two-tailed). Differences were considered significant with p#0.5.
Supporting Information
Table S1 Evidence of Productive Infection in Experi-
mental Animals (Experiment 2).
(DOC)
Table S2 Xenodiagnostic Ticks Recovered (Experiment
2).
(DOC)
Figure S1 The decline in C6 antibodies that accompa-
nied antibiotic treatment in Experiment 2. Animal
designations in bold (black lines) indicate those that were treated.
Antibody levels indicated by gray lines are from the untreated
animals.
(TIF)
Figure S2 RNA samples tested for DNA contamination
with Taq polymerase PCR. Samples included the 100 bp
ladder (M), no template control (ntc), B. burgdorferi DNA (Bb DNA),
B. burgdorferi RNA (Bb RNA), monkey DNA (Mk DNA) and
monkey RNA (Mk RNA).
(TIF)
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